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Abstract
Individuals with anorexia nervosa (AN) restrict eating and become emaciated. AN tend to have an 
aversion to foods rich in fat. Because Epoxide Hydrolase 2 (EPHX2) was identified as a novel AN 
susceptibility gene, and because its protein product, soluble epoxide hydrolase (sEH), converts 
bioactive epoxides of polyunsaturated fatty acid (PUFA) to the corresponding diols, lipidomic and 
metabolomic targets of EPHX2 were assessed to evaluate the biological functions of EPHX2 and 
their role in AN.
Epoxide substrates of sEH and associated oxylipins were measured in ill AN, recovered AN, and 
gender- and race-matched controls. PUFA and oxylipin markers were tested as potential 
biomarkers for AN. Oxylipin ratios were calculated as proxy markers of in vivo sEH activity. 
Several free- and total PUFAs were associated with AN diagnosis and with AN recovery. AN 
displayed elevated n-3 PUFAs and may differ from controls in PUFA elongation and desaturation 
processes. Cytochrome P450 pathway oxylipins from arachidonic acid, linoleic acid, alpha-
linolenic acid, and docosahexaenoic acid PUFAs are associated with AN diagnosis. The 
diol:epoxide ratios suggest the sEH activity is higher in AN compared to controls. Multivariate 
analysis illustrates normalization of lipidomic profiles in recovered ANs.
EPHX2 influences AN risk through in vivo interaction with dietary PUFAs. PUFA composition 
and concentrations as well as sEH activity may contribute to the pathogenesis and prognosis of 
AN. Our data support the involvement of EPHX2-associated lipidomic and oxylipin 
dysregulations in AN, and reveal their potential as biomarkers to assess responsiveness to future 
intervention or treatment.
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INTRODUCTION
Anorexia nervosa (AN) is a serious eating disorder with a reported prevalence ranging from 
0.24 to 4.3%.[1] While it is one of the less prevalent major psychiatric diseases, it is the 
deadliest of all psychiatric illnesses.[2, 3] Patients with AN restrict eating and become 
emaciated, yet the relentless behavior to achieve thinness by restrictive eating continues 
together with distorted body image and profound fear of weight gain. Although it has 
traditionally been speculated that factors contributing to AN are social and psychosocial in 
origin, recent findings demonstrated that genetic factors account for approximately 50 to 
80% of the AN risk[4], suggesting that the pathophysiology of AN involves the complex 
interplay of biological, biochemical, and environmental risk factors.
Patients with AN have long been known to experience fat aversion and avoidance of fat-rich 
foods.[5, 6] The diet preferred by AN is typically low in total proteins, carbohydrates, 
polysaccharides, and fats.[7, 8] Additionally, pre-meal anxiety in AN was found to be 
correlated with consumption of high fat food like macaroni and cheese (42.2% fat) but not 
for a low-fat yogurt snack (12.9% fat). [9] The illness duration of AN is negatively 
correlated with the amount of dietary fat in both acute and chronic patients.[8] However, the 
reason for fat avoidance in AN patients is not well understood.
Fat-rich foods serve as one of the primary sources of essential fatty acids (EsFA), including 
omega-3 (n-3) and omega-6 (n-6) polyunsaturated fatty acids, which are critical for brain 
development, aging and general health.[10, 11] Frank EsFA deficiency, though rare from a 
purely dietary perspective, is associated with a number of cardio-metabolic, neurological, 
immunological and psychiatric diseases.[12] While essential fatty acids are influenced by 
diet, their biological functions and health consequences are also dependent on a number of 
diverse enzyme families for biosynthesis and modulation of resulting lipid mediators that 
goes far beyond being structural building blocks. Earlier studies in AN populations have 
found the presence of altered fatty lipid levels[13] that have been attributed to malnutrition 
partly based on findings from the pediatric population studies that showed associations 
between malnutrition and abnormalities in fatty acid profile[14, 15]. However, an earlier 
study in AN suggested that fatty acid alterations in AN differ from simple nutritional 
essential fatty acid deficiency or chronic malnutrition.[16] To account for the effect 
malnutrition specific to ill AN (active disease) has on lipidomic disturbances and to 
determine by what extent AN recovery normalizes these disturbances, we studied both ill 
AN and recovered AN together with healthy controls.
Through our recent targeted exomic individual and pooled sequencing discovery and 
multiple stage replication study, the Epoxide Hydrolase 2 gene (EPHX2) was found to 
harbor several common and rare risk variants for AN.[17] EPHX2 codes for soluble epoxide 
hydrolase (sEH), a key gate-keeper enzyme that affects lipid signaling functions of a broad 
range of metabolites by the catabolism of epoxy-fatty acids to their corresponding diols.[18] 
[19, 20] This sEH activity reduces the potency of anti-inflammatory epoxy-fatty acids (e.g. 
epoxy-eicosatrienoic acids [EpETrEs] from arachidonic acid [ARA]), thereby affecting 
human health through modulation of the biologically active lipid mediators.[21] Epoxy-fatty 
acid substrates of sEH include the epoxides derived from n-3 lipid, such as docosahexaenoic 
Shih et al. Page 2
Mol Psychiatry. Author manuscript; available in PMC 2016 May 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
acid (DHA) and eicosapentaenoic acid (EPA), and from n-6 lipid, such as arachidonic acid 
(ARA), linoleic acid (LA), and stearic acid (SA).[22] The sEH activity is highest in the liver 
and kidney and it is also found to be highly expressed in multiple other organs and tissues 
including the brain [23] and adipose tissue.[24] It has been suggested that since sEH is 
localized in neurons of the central amygdala, it may play a role in neuronal firing.[25] Thus, 
it is proposed that sEH acts in the brain through the metabolism of lipid mediators to 
modulate the release of neurotransmitters that influence cognition, affect, and eating 
behaviors that are key characteristics for AN. The discovery of EPHX2 as a risk gene for 
AN raised the possibility that fat-avoidance in AN could in part be due to some intrinsic 
biological process that is associated with sEH lipid regulatory functions.
Taken together, our discovery of EPHX2 variant association with AN[17] and current 
literature support the hypothesis that sEH, through biological interaction with 
polyunsaturated fatty acid substrates, plays a role in fat aversion in AN and the 
pathophysiology of disordered eating. We developed an integrative study to investigate 
downstream lipidomic targets of sEH to understand the mechanisms by which EPHX2 
influences AN pathophysiology.
SUBJECTS AND METHODS
Study Design
This is a cross-sectional study designed to characterize plasma n-6 and n-3 PUFAs and their 
oxylipin derivatives in two groups of AN (ill and recovered) and healthy controls for two 
purposes: 1) to explore functional consequences of sEH in the PUFA pathway and assess if 
they contribute to AN risk, and 2) to test the feasibility of targeted (sEH associated) PUFA 
and oxylipin markers as biomarkers for AN and associated key temperament traits.
Subjects
We selected 30 ill AN (median age: 20 years; age range: 16–34 years), 30 recovered AN 
(median age: 22 years; age range: 18–38 years), and 36 controls (median age: 20 years; age 
range: 18–26 years) to test our hypothesis that sEH modulation of dietary polyunsaturated 
fat and oxylipins may result in dysregulated metabolism and increased AN risk. The cases 
and controls were chosen from the original Price Foundation Genetic Study 
biorepository[26] based on subjects’ AN disease subtype (restricting AN), extreme low body 
weight for ill AN (to maximize study power by contrasting the severely illness to recovered 
AN), and bio specimen availability. Cases selected for this study were women of European 
decent, selected from the Price Foundation AN Trio Study. [26] All cases were required to 
meet the following criteria: (a) modified DSM-IV lifetime diagnosis of AN, i.e., with or 
without amenorrhea; (b) onset before the age of 25 years; (c) age between 13 years and 40 
years; (d) self-identified European ancestry; (e) no lifetime history of binge eating; and (f) 
study diagnostic criteria were met for at least 3 years before study entry. A diagnostic 
hierarchy was then applied to define AN subtypes: restricting AN, AN with purging but no 
binge eating, AN with binge eating with or without purging, and a lifetime history of both 
AN and BN (ANBN).[27] We selected only restricting AN subtype to ensure a 
homogeneous sample of cases given the hypothesized relationship between restrictive eating 
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behavior and sEH pathway. The restricting AN subtype is characterized by fiercely limiting 
the food consumed that is well below their body’s caloric needs, essentially an act of chronic 
starvation. The ill AN cases (IAN) in this study are defined as having ongoing ED symptoms 
and BMI of equal or less than 17.5 kg/m2 in the past year; whereas the recovered AN cases 
(RecAN) are defined as having an absence of ED symptoms in the past year including 
maintenance of a BMI of 18 kg/m2 or greater. The healthy control women were chosen from 
the control group[26] and were (a) between the ages of 18–40 years; (b) at normal weight 
with lifetime adult BMI between 19 kg/m2 and 27 kg/m2; and (c) gender and ethnicity 
matched to the cases. The exclusion criteria for controls were: (a) reported history of an 
eating disorder or eating disordered behaviors; (b) had a first degree relative with an eating 
disorder; or (c) had any psychiatric, alcohol or drug use disorder defined by the presence of 
an Axis I disorder on the SCID Screen Patient Questionnaire.[28] Informed consent was 
obtained from all study participants, and all sites received approval from their local 
Institutional Review Board.
Isolation of Plasma
Polyunsaturated fatty acid and oxylipin assays were performed using banked plasma from 
selected subjects. Whole blood was collected in EDTA vacutainer tubes and plasma was 
separated by centrifugation at 1350 rpm for 10 minutes and removed with a pipet and then 
frozen at −80C.
Polyunsaturated Fatty Acid Measurement
Both free (non-esterified) and total (esterified) forms of fatty acids were measured in plasma 
of all AN cases (30 IAN, 30 RecAN) and 36 controls collected from their baseline visit. The 
free fatty acids were purified and enriched with the application of a bi-phasic solution of 
acidified methanol and isooctane. A set of deuterated fatty acids was added to the samples to 
serve as internal standards for quantitation and to compensate for any losses during the 
analytical procedure. Gas chromatography coupled with mass spectrometry (GC/MS) was 
used to quantify each fatty acid, as previously described.[29] For the total fatty acid 
measurement, a hydrolysis step with KOH was used to release the fatty acids from the 
triglyceride and phospholipid backbone.[29] While the readout of the PUFA assay include 
markers consisting of saturated-, monounsaturated-, and polyunsaturated-fatty acids, we 
analyzed only the omega 6 (n-6) and omega 3 (n-3) fatty acids and prioritized the well-
established sEH PUFA substrates (n-3 [EPA, DHA, ALA] and n-6 [ARA, LA] fatty acids) as 
the primary variables for association analysis. These markers reflect the nutritional-based 
PUFA profile and their metabolites which are biologically active lipid mediators, and also 
serve as proxy markers for in vivo sEH activity. Concentration of each fatty acid was 
measured in the unit of µmol/L and reported as a percentage of total plasma fatty acid as 
described in Table 2 of our previously published work.[29]
Targeted Metabolomics - Oxylipin Measurement
A targeted metabolomics assay was carried out using plasma of 10 ill AN, 10 recovered AN, 
and 38 controls to identify sEH associated metabolomic biomarkers. The targeted oxylipin 
assay was designed based on the pathway of n-3 and n-6 polyunsaturated fatty acid 
precursors as described previously.[30, 31] The assay results in read-out of 80 individual 
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oxylipins, of which 12 are direct substrates of sEH (epoxy fatty acids: EpOMEs from 
linoleic acid, EpETrEs from arachidonic acid etc.), 12 are catalyzed products of sEH 
(DiHOMEs from linoleic acid, DiHETrEs from arachidonic acid etc.). The remaining 9 
oxylipins are metabolites associated with actions of a suite of enzymes, including those in 
the cyclooxygenase (COX), lipoxygenase (LOX), and cytochrome P450 (CYP) families 
(Supplement Table 2). In brief, these metabolite markers were prepared by solid phase 
extraction using Oasis HLB cartridges followed by reversed phase HPLC analysis utilizing 
C18 columns.[32] The analytes elute according to their polarity with the most polar analytes, 
prostaglandins and leukotrienes, eluting first followed by the hydroxy and epoxy fatty acids. 
The separated analytes were then quantified by tandem mass spectrometry in multiple-
reaction monitoring mode utilizing negative electrospray ionization for the oxylipin 
profiling. Surrogate analytes and internal and external standards will be used to monitor 
extraction efficiency and ensure accurate quantitation of analytes. A random selection of 
10% of the samples was replicated for validity testing. Quality control samples were 
analyzed at a minimum frequency of 10 hours to ensure stability of the analytical calibration 
throughout a given analysis.
Data Processing and Statistical Analysis
All polyunsaturated fatty acid (PUFA) and oxylipin data were assessed for normality with 
histograms. When non-normality was detected, values were log transformed prior to 
analysis. Significance was set at P<0.05; no adjustments were made for multiple testing due 
to the exploratory and hypothesis-driven nature of the analyses. PUFA and oxylipins with 
>30% missing observations were excluded, observations that were >4 SD from the mean 
were excluded. Change-detection plots were used to determine whether the observed signal 
was greater than that which could be expected by chance (noise). Absolute concentrations of 
oxylipin are presented as nmol/L; percentage of total PUFA in unit measure of umol/L is 
used to report PUFA concentration.
Tests of univariate association were conducted using Pearson's product moment correlation 
coefficient test and ANOVA using the statistical analysis tools in R (version 2.14.2).[33] 
Multivariate statistical analysis was employed to explore patterns in the overall PUFA (n-3 
and n-6 classes) and oxylipin profiles of two group of AN subjects (Ill AN and recovered 
AN) and healthy controls; partial least-squares discriminant analysis (PLS-DA) was used as 
the classification method for modeling the discrimination between the groups using SIMCA-
P software (version 12.0.1; Umetrics, Umea, Sweden) as previously described. [34] Briefly, 
data were mean centered and unit variance scaled. Unsupervised principal component 
analysis (PCA) was applied to all samples (Total n=96 for PUFA data and 58 for oxylipin 
data) and scores plots were visually inspected for trends or outliers in the data. Partial least-
squares discriminant analysis (PLS-DA) was then used to explore variations in PUFA and 
oxylipin levels between different classes (IAN versus RecAN versus controls). A scores plot 
was created to visualize the PLS-DA model, and the corresponding loadings provided 
information on the contribution of metabolites to the separation of classes. The principal 
component that explains the best phenotype variance per PCA graph was tested by ANOVA 
to determine if this component is significantly different among and between groups.
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Quantitative trait phenotype (subjects characteristics, Table 1) and oxylipins (Figure 2 and 
Supplement Table 2) were log-transformed for the standardized parametric inferential 
statistic tests. The PUFA and oxylipin markers were reformulated as ratios and used as 
markers of essential fatty acid balance (e.g.: n-6:n-3 fatty acid ratios) and sEH in vivo 
enzyme activity (metabolites/substrates), respectively. The correlation between the free form 
of fatty acids and matrix-bound total fatty acids was tested using Pearson's product moment 
correlation coefficient. PUFA and oxylipins were tested for association with the primary 
phenotypes of interest (AN risk, An recovery status) with ANOVA with age as covariate. 
Individual and ratio markers that were found to be significantly associated with AN risk 
were tested for association with eating disorder relevant temperament phenotypes using 
Pearson’s correlation coefficient.
RESULTS
Participants and Phenotypes
Demographic and phenotypic characteristics of the 60 AN women (all restricting anorexia 
nervosa consisting of 30 ill AN [IAN], 30 recovered AN [RecAN]), and 36 healthy control 
women are summarized in Table 1. Body mass index (BMI) was significantly different 
between AN and controls (p-values: <0.00001) and between IAN and RecAN (p-value 
<0.00001). Beck Depression Inventory (BDI), state anxiety and trait anxiety scores from the 
State-Trait Anxiety Inventory (STAI), and “harm avoidance” and “novelty seeking” from the 
Temperament and Character Inventory (TCI) were also significantly different between AN 
and controls (p-values: < 0.0001, Table 1) and between IAN and RecAN (p-values: 0.005 to 
<0.0001, Table 1). Subjects with AN were significantly more depressed, having higher 
anxiety, higher harm avoidance, and lower novelty seeking scores than controls. Total 
cholesterol and HDL levels were significantly higher in IAN compared to controls (p-
values= 0.016 and 0.004), consistent with the literature.[35, 36]
Non-esterified and Esterified Polyunsaturated Fatty Acids
Plasma specimens of all subjects were used to measure concentrations of non-esterified fatty 
acids (NEFA) and esterified fatty acids (EFA - fatty acids covalently bound to complex 
lipids) in two major structural isomer categories, omega 6 (n-6) and omega 3 (n-3). Of the 
eight n-6 fatty acids measured (LA, GLA, EDA, DGLA, ARA, 13/16-DA, ADA and OBA), 
four (LA, GLA, ADA and OBA) were significantly correlated between the NEFA and EFA 
(r=0.23 – 0.77, p-values: 0.02 – 7.7E-10). Out of the six n-3 fatty acids measured (ALA, 
SDA, ETE, EPA, DPA and DHA), five (ALA, SDA, EPA, DPA, and DHA) were 
significantly correlated between the NEFA and EFA (r=0.32 – 0.63, p-values: 0.001 – 
2.2E-16) (Supplement Table 1).
The concentrations of three n-6 (DGLA, ARA and OBA) and four n-3 (ALA, SDA, EPA and 
DHA) NEFAs were significantly different among three groups (IAN, RAN, Controls) 
(Figure 1A and Supplement Table 3). NEFA forms of GLA, DGLA, OBA, ALA, SDA, and 
EPA were significantly different between IAN and controls (p-values: <0.0001 to 0.03, 
Supplement Table 3). OBA and SDA concentrations were significantly higher in IAN 
compared to RecAN (p-values: 0.042 and 0.006, Supplement Table 3). OBA and SDA were 
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correlated with BMI only in the AN group. In EFA form, only two n-6 (ARA and OBA) and 
two n-3 (ALA and DPA) EFAs were significantly different among IAN, RecAN, and 
controls (Figure 1B). EFA OBA concentration was significantly higher in IAN than RecAN 
(p-value= 0.002) whereas DPA was higher in RecAN than IAN (p-value= 0.009)(data not 
shown). EFA OBA and DPA were associated with BMI only in subjects with AN but not in 
the controls.
Fatty Acid Ratio Associations
Nine PUFA ratio markers were formulated to infer the balance between n-6 and n-3 PUFAs 
and enzymatic activity in PUFA synthesis. Among NEFAs, LA:ALA and ARA:EPA ratios 
were lowest in IAN, followed by RecAN, and highest in controls (three-group comparison p-
values: 0.0016 and 0.001, pair-wise comparison p-values please see Table 2). In comparison, 
EPA:DPA, EPA:DHA and DHA:DPA were significantly higher in both IAN and RecAN 
compared to controls, with IAN showing the highest ratios and controls the lowest (three-
group comparison p-values: <0.001, pair-wise comparison p-values please see Table 2). 
None of the IAN-associated ratios were significantly different in RecAN compared to 
controls except for LA:ALA (p-value= 0.018, Table 2 Upper). Similar patterns of association 
were identified in EFA ratios, except that none of the EFA PUFA ratios was significantly 
different between RecAN and controls (Table 2 Lower).
Oxylipin Quantification and Association
Oxylipins are produced from PUFA precursors and are derived from the actions of a suite of 
enzymes, including those in the cyclooxygenase (COX), lipoxygenase (LOX), and 
cytochrome P450 (CYP) families, as well as by non-enzymatic oxidation.[30] Oxylipins 
were measured in the plasma of all subjects. The descriptive statistics of all oxylipins 
assayed, which consist of 24 sEH-associated oxylipins and their ratio markers (n=12) and 9 
non-CYP450 pathway oxylipins, are presented in Supplement Table 2. To assess data 
validity, we confirmed that ARA oxylipins 14.15.EpETrE and 14.15.DiHETr fall within the 
range that has been validated as potential clinical trial biomarker.[37]
Focusing in on oxylipins that are sEH substrates and catalyzed products, significant 
differences between ANs and controls were observed both in individual oxylipins and ratios 
of oxylipins (metabolites/substrates) which mark in vivo sEH efficiency and activity.[38] 
AN-associated (IAN compared to controls) oxylipins are DHA metabolites 10.11.EpDPE (p-
value = 0.049), 13.14.EpDPE (p-value = 0.039) and ARA’s metabolite 9.10.EpOME (p-
value = 0.05)(Supplement Table 2). The oxylipin ratios from n-3 (ALA and DHA) and n-6 
(ARA and LA) PUFAs were significantly different among three groups and were higher in 
IAN compared to controls (Figure 2 and Supplement Table 2), suggesting a higher in vivo 
sEH activity, concentration, or efficiency in AN.
To compare and contrast the sEH- associated oxylipins (Cyp450 pathway) with those that 
are modulated by other major enzymatic pathways, we examined the levels of oxylipins 
from the COX pathway (TXB2, PGE2, PGD2) and the LOX pathways (LTB4 and various 
HETEs), and found no evidence of differences between cases and controls (Supplement 
Table 2).
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Multivariate Analysis
Multivariate statistical procedures were employed to compare total PUFA (n-3 and n-6 
markers combined) and oxylipin profiles between IAN, RecAN and controls. The most 
informative two components of the PCA accounted for 31% and 27% of the variation in the 
PUFA data and oxylipin data, respectively (Figures 3A and 3B). Visual inspection of the 
PUFA scores plot indicates separation of IAN subjects from controls; whereas the recovered 
AN appeared to overlap equally well with both the IAN and controls (Figure 3A). The top 
10 predicted lipidomic (PUFA) biomarkers are: non-esterified (NE) EPA:DPA, NE 
ARA:EPA, NE SDA (18:4n3), NE EPA:DHA, NE OBA (22:5n6), NE EPA (20:5n3), 
esterified OBA (22:5n6), esterified ARA:EPA, NE ALA (18:3n3), and NE LA:ALA.
The oxylipin PCA plot showed IAN subjects separate clearly from controls, whereas RecAN 
showed compelling overlap with controls and limited overlap with IAN (Figure 3B). The top 
10 predicted oxylipin biomarkers are: 19(20)-DiHDPE:EpDPE, 19(20)-DiHDPE, 10(11)-
DiHDPE:EpDPE, 12(13)-DiHOME, 15(16)-DiHODE, 8(9)-EpETrE, 9(10)-DiHOME, 
14(15)-DiHETrE:EpETrE, 5(6)-DiHETrE:EpETrE and 13(14)-EpDPE. The PCA scores 
plots illustrated a closer clustering between RecAN with controls in oxylipins than in PUFA 
profiles.
PUFA and oxylipin marker association with anorexia nervosa temperament and lipid 
phenotypes
PUFA ratios and oxylipin markers that were significantly associated with AN risk, were 
tested for associations with AN-specific phenotypes: BMI, depression score, anxiety, novelty 
seeking and harm avoidance scores. Both non-esterified (NE) and esterified forms of 
ARA:EPA ratios were significantly correlated with state anxiety (r= −0.363 and −0.378, p-
values=0.029 and 0.022, respectively for NEFA and EFA) and trait anxiety (r= −0.358 and 
−0.525, p-values=0.032 and 0.001, respectively) in controls but not in ANs. In ANs, the NE 
ARA:EPA and LA:ALA were associated with state anxiety (r= −0.261 and −0.268, p-
values=0.04 and 0.04, respectively). While ARA:EPA ratio showed no association with BMI 
in controls, both NE and esterified ARA:EPA significantly correlated with BMI in AN (r= 
0.415 and 0.371, p-values=0.0009 and 0.0035, respectively).
NEFA and esterified EPA:DPA and EPA:DHA ratios significantly correlated with BMI in 
AN but not in controls (For EPA:DPA: r= −0.392 and −0.293, p-values=0.002 and 0.022. For 
EPA:DHA: r= −0.433 and −0.318, p-values=0.0005 and 0.013). NE form of the DHA:DPA 
ratio was associated with state anxiety and trait anxiety in controls only (r= 0.393 and 0.404, 
p-values=0.017 and 0.014).
DISCUSSION
Twin and discordant sister pair studies found evidence of not only individual environmental 
and genetic factors[39], but also gene-environment interactions[40] contributing to AN risk. 
Dieting is a common practice in adolescents and dietary behaviors always precede the onset 
of AN. However, only a very small fraction of dieters become sick with AN,[41, 42] 
supporting the heritability study finding that genetic predisposition is necessary for AN risk 
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(first hit). Additional insults from non-genetic factors are also required for the disease onset 
(second hit).
AN differs from other eating disorders by a homogeneous clinical presentation of restricting 
food intake. The determination to maintain low body weight and reported food aversion are 
attributed to high levels of chronic anxiety, which does not seem to improve with weight 
restoration.[43] Anxiety and extreme eating behavior are thought to be affected by a 
combination of genetic, biological, psychological, and social factors.
Soluble epoxide hydrolase is the protein product of EPHX2. It is known for a key role in fat 
metabolism by modulation of bioactive lipids.[44] sEH catalyzes multiple epoxy-fatty acids 
and transforms anti-inflammatory epoxides to pro-inflammatory metabolites.[21] The 
transformative role sEH plays in the inflammation cascade through oxylipin modulation may 
therefore contribute to the “aversive sensation” associated with consumption of fat-rich 
foods reported by AN. In parallel, restrictive eating from dieting that precede the AN 
diagnosis, could lead to depletion of essential nutrition including PUFA that the brain needs 
for neuro-circuitry formation, leading to “switch-off” of protective neuronal- and 
biochemical-based mechanisms in those genetically susceptible.[45] Moreover, depletion of 
PUFA through insufficient dietary intake could also adversely affect metabolic regulatory 
function of sEH by limiting the substrate access, or skewing the optimum n6:n3 substrate 
ratio. To better understand how genetic and non-genetic risk factors work together to 
influence risk for AN, here we utilize metabolomics data that infer the in vivo activity of 
sEH, fatty acids markers that reflect relative nutritional status, and two groups of AN and 
controls to explore the evidence of gene-by-environment interaction and to clarify the roles 
dietary PUFA and sEH have on AN.
PUFA associating with AN status, BMI, and temperament traits
Fat-rich foods serve as one of the primary sources of two major classes of essential fatty 
acids, n-3 and n-6 polyunsaturated fatty acids. The alpha-linolenic acid (ALA) and linoleic 
acid (LA) are parental compounds for the n-3 and n-6 fatty acid metabolic families. Several 
groups have previously reported decreased dietary consumption of PUFA in AN,[46] and 
association of AN with abnormal PUFA levels and desaturase activity.[13, 16, 47–51] Data 
from a small number of pilot treatment studies indicate that n-3 supplement may have a 
beneficial effect on AN symptoms.[52, 53]
In our samples, the AN show elevated concentration in plasma n-3 fatty acids (ALA, SDA, 
EPA, DHA) compared to controls (Figure 1A and Supplement Table 3). The step-wise 
decrease of n-3 EsFA parental compound (ALA) from IAN to RecAN to controls coupled to 
no difference in n-6 EsFA parental compound (LA) may be explained in part by patients’ 
general preference of foods rich in n-3 PUFA such as leafy greens and fish. In humans, ALA 
and LA are metabolized by desaturase enzymes to long-chain unsaturated fatty acids 
through a series of elongation and desaturation steps.[54] The n-3 and n-6 fatty acids 
compete for the desaturation and elongation enzymes, and the Delta 5 and Delta 6 
desaturases tend to “favor“ the n-3 fatty acids.[55] Therefore, any consideration given to 
health effects of one fatty acid class should take into account the presence and relative 
abundance of the other families of fatty acids, as well as the metabolic relations between 
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them. The AN who are recovered may get there by increasing meat-based foods thereby 
improving the n6:n3 ratio and ALA concentration.
The desaturated and elongated versions of long-chain n-3 PUFAs, EPA and DHA, were also 
elevated in AN compared to controls (Figure 1A and Supplement Table 3). Elevated 
EPA:DPA and DHA:DPA ratios (Table 2) in AN suggest altered efficiency in elongation and 
desaturase activities in AN, consistent with Holman et al’s 1995 proposal of a deficiency in 
the elongation step and delta-5 desaturation step of EFA conversion in AN.[16] Other 
possible factors that contribute to the long-chain n-3 PUFA ratio differences include an 
increased precursor ALA in AN, and differential rate and expenditure of EPA and DHA 
during the enzymatic catalysis process. Together, the striking elevation of n-3 PUFAs reveal 
that contrary to expectation, enrichment of EPA and DHA in patients with AN should not be 
assumed to be protective as reported for other neuropsychiatric illness such as Alzheimer’s 
and major depression.[56, 57]
The concentration of esterified arachidonic acid (ARA) was significantly different among 
three groups (p=0.02, Figure 1B) and was shown to be lowest in IAN compared to controls; 
whereas the NE form of ARA was also significantly different among three groups (p=0.03, 
Figure 1A) but has the highest level observed in the RecAN group (Figure 1A). This striking 
pattern difference between esterified ARA and NE ARA might be attributed to the 
preferential agonist-induced ARA release mediated by cytosolic phospholipase A2 (cPLA2).
[58] While NEFA may reflect acute changes in the metabolic profile, EFA provide a less 
dynamic, more chronic read-out of metabolic state. Our data show that NEFA and EFA 
species of each major FA were significantly correlated except for ARA (Supplement Table 
1). The differential profile observed in NE and esterified forms of ARA suggests that the 
preferential substrate selectivity of the cPLA2 [59] may influence the variability of 
circulating NE ARA better than its esterified form.
The findings that both esterified ARA:EPA and LA:ALA ratios were lowest in IAN, 
followed by RecAN and were highest in controls (Table 2) highlight the imbalance of 
n-6:n-3 ratio in AN. A recent study in healthy adults showed that fish oil intervention 
resulted in increased appetite.[60] Given the observed significant increase of n-3 PUFA 
concentrations in AN, potential beneficial effects of fish oil to improve appetite for AN 
needs to be rigorously studied before conclusion can be drawn. While previous AN studies 
have already shown correlations between n-3 PUFA and body weight[47, 48, 50] or 
depression[46, 47, 49], no report of direct association between PUFA and key temperament 
traits in AN was available. Temperament is the biologically based characteristic that 
contributes to major psychological processes through the expression of consistent patterns of 
feeling, thinking, and behavior. Specific temperament traits such as increased anxiety[61, 
62], increased harm avoidance[63], and decreased novelty seeking[43, 62] are tightly linked 
to AN (Table 1).[43] PUFA ratio markers were found to be differentially associated with a 
number of temperament phenotypes such as state anxiety and trait anxiety in AN compared 
to controls. Furthermore, a number of ratio markers show striking associations with BMI in 
AN only but not in controls, suggesting the dysregulated PUFA markers to be specific to 
AN.
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Multivariate PCA analysis of all PUFA markers revealed distinct patterns in IAN, RecAN, 
and controls. Consistent with the individual marker results, IAN and controls are clustered 
with clear separation, whereas RecAN tend to cluster with both IAN and controls, 
demonstrating the process of PUFA profile normalization during the recovery phase of AN 
(Figure 3A) that may be attributed to dietary improvement, increased body fat, or changes in 
PUFA elongase and desaturase enzymes and metabolic rate. Taken together, the PUFAs may 
not only be useful markers of disease itself but may also contribute to temperament traits 
that drive persistent restrictive eating and prognosis.
Oxylipin markers reveal differential sEH activity in AN and controls
Among all the oxylipin markers examined, sEH-product to substrate ratios (diol:epoxide 
ratios) derived from the ARA, LA, ALA and DHA PUFA were all associated with AN 
status, but the most striking ratio predictors were those of ALA and DHA (Figure 2 and 
Supplement Table 2). These ratios are proxy markers of sEH activity.[64] The ratios of most 
PUFA metabolites are significantly different among groups and are higher in AN (Figure 2 
and Supplement Table 2), which suggests elevated in vivo sEH activity in AN patients. 
These biomarkers validate the functional significance of the EPHX2 gene with AN and 
demonstrate that the epoxy-fatty acid-modulatory action of sEH may be a key mechanism by 
which EPHX2 affects AN risk. [17]
ARA is a substrate for three major enzymatic routes of metabolism by cyclooxygenase, 
lipoxygenase, and cytochrome P450 enzymes. The AN-associated oxylipin markers 
identified in this study were ratio markers that serve as surrogate for sEH activity within the 
cytochrome P450 pathway. Given the possibility that oxylipin-disease associations may also 
be attributed to the upstream fatty acids, we analyzed oxylipin markers of ARA that are 
derivatives of cyclooxygenase and lipoxygenase actions as “controls” to assess the 
specificity of EPHX2/cytochrome P450 pathway in AN biology. Across all cyclooxygenase 
and lipoxygenase associated oxylipins measured, including thromboxane, prostaglandins 
and leukotriene, none were significantly different between AN and controls (Supplement 
Table 2). Taken together, our data indicate that sEH activity is elevated in AN, and may 
increase disease risk through sEH-modulated mechanism of transforming anti-inflammatory 
epoxy to unstable diol forms to induce cellular inflammation.
The inflammation link to AN observed by elevated sEH action and dysregulated oxylipin 
markers was re-assessed using multivariate analysis. In principle, if the inflammatory state is 
associated with or precedes the disease onset, the recovery status in subjects with AN should 
also link to normalization of the dysregulated biomarkers. Indeed, the oxylipin PCA profile 
(Figure 3B) showed a differential clustering of IAN and controls while RecAN appears to be 
overlapping with controls and not with IAN. By contrast, RecAN show equal overlap with 
both IAN and controls in the PUFA PCA model (Figure 3A), indicating a “slower” 
normalization of the PUFA profile in the RecAN group. Taken together, the interconnected 
lipidomic and metabolomic profiles reveal the biology of evolving disease state in AN.
We identified that sEH activity within the cytochrome P450 pathway plays a key role both in 
AN risk and recovery status. In the presence of increased n-3 PUFA in AN, the metabolite/
substrate ratios derived from both n-3 and n-6 PUFA oxylipins indicate that in vivo sEH 
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activity is an independent risk factor for AN risk and prognosis. The comparison of total 
lipidomic and oxylipin profiles further suggests that the resolution of presumed sEH-
associated inflammation is apparent in AN who are recovered, even if the PUFA profile has 
not normalized completely. This process could occur in several ways including alterations of 
sEH, P450 pathway produced fatty acid epoxides, PUFA from membranes, or dysregulation 
from other metabolic pathways.
Prior EPHX2 variant associations and implications
EPHX2 variants found to be associated with AN risk were in the 3’ region of the gene as the 
5’ region of EPHX2 was not sequenced due to limitations in the method.[17] Some of the 
AN-associated SNPs were also associated with increased depression and anxiety in AN, and 
decreased longitudinal increase in BMI over cholesterol trajectories in controls.[17] 
However, common 3’ EPHX2 SNPs associated with AN (rs2291635, rs1042064 and 
rs4149259) are found in variable linkage disequilibrium with two non-synonymous EPHX2 
SNPs that have been the subject of numerous enzyme activity and cardiovascular association 
studies (rs41507953 [Lys55Arg] and rs751141 [Arg287Gln]) with pairwise r2 of 0.01 and 1, 
0.21 and 0.33, and 0.41 and 0.02, respectively, in HapMap CEU (Supplement Figures 1A 
and 1B).
In the first in vitro EPHX2 expression study, the Arg 55 and Gln 287 alleles were found to 
be associated with elevated and reduced hydrolase activity, respectively.[65] Based on the 
reported under-representation of the rs2291635 minor allele in AN[17] and the pairwise r2 of 
1 between rs2291635 and rs751141 from the HapMap CEU sample, we infer that the Gln 
287 allele with reduced hydrolase activity is under-represented in AN cases, or that the Arg 
287 allele with reference hydrolase activity is over-represented in AN cases, which is 
consistent with our finding that in vivo sEH activity is elevated in AN.
EPHX2 SNPs have been found to associate with multiple metabolic or cardiovascular 
phenotypes. rs41507953 (Lys55Arg) has been associated with elevated in vivo sEH and 
coronary heart disease[66] [66], vasoconstriction[67], SBP and male ischemic stroke[68] in 
European ancestry populations. rs751141 (Arg287Gln) has been associated with coronary 
artery calcification[69], atherosclerosis[70], and vasodilation in response to endothelial 
regulators of blood pressure in African American ancestry individuals.[67] rs751141 was 
also associated with reduced insulin resistance in Japanese [71] and protection against 
kidney failure in Koreans.[38] In European ancestry populations, rs751141 has been found 
to associate with coronary artery calcified plaque[72], stroke[73], blood pressure in men[68], 
atrial fibrillation recurrence[74], and insulin sensitivity.[75] The 3’ variants that are 
associated with AN have been less studied although associations were found between 
rs2291635 and stroke[73] whereas rs1042032 was associated with blood pressure with 
gender-interaction effect (significantly increased in males, non-significantly decreased in 
females)[68], kidney failure[38], and expression.[76] Furthermore, Wei et al in the CARDIA 
cohort identified that a significantly associated haplotype in African Americans was tagged 
by a different SNP than the haplotype-tagging SNP in European ancestry individuals.[70]
Together, these studies point to effects of functional EPHX2 variants on sEH activity and of 
resulting metabolites’ biological functions to be under the influence of gender and race, 
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however, little is known about the direct influence of gender and race on the oxylipin 
biomarkers. To bridge the gap in this knowledge, our study took the first step to 
comprehensively characterize the metabolomic profile (oxylipin) of the EPHX2 pathway in 
European ancestry female psychiatric patients and population-based samples.
Unique strength of this study
Twin and discordant sister pairs studies found evidence of not only individual environmental 
and genetic factors[39] contributing to AN but also gene-environment interactions.[77] 
Taking the PUFA and oxylipin data together, we demonstrated the contributions from gene, 
diet, and their interaction to AN: while the oxylipin biomarkers implicate elevated sEH 
activity as a risk factor for AN as hypothesized through an established genetic 
susceptibility[17], the dysregulated EsFA and PUFAs observed in both ill and recovered AN 
suggest the adverse effect of poor diet on AN.[78] We provide evidence that the activity of 
the sEH, the substrates of the sEH (epoxy fatty acids), and the metabolomic derivatives 
(oxylipins) and their collective readout reflect changes in disease state and risk of AN. This 
finding has unraveled evidence of one specific gene-environment interaction and highlighted 
the importance of fatty acid lipid metabolism in AN risk and prognosis. From the clinical 
point of view, this study provides a comprehensive assessment of dietary fatty acid profile in 
which confirms the importance of malnutrition in disease risk. Taken together, pathway-
specific biological targets, both nutritional and pharmaceutical, may be investigated further 
to develop more effective prevention and treatment strategies.
Limitation of this study
Our study reveals the contributing roles a deregulated lipidomic pathway and a functional 
gene have on AN. While the differences in PUFA profiles in AN and controls may be 
partially explained by differences in dietary behavior, in the absence of food intake history 
we could only use EsFA levels as proxy markers to infer the influence of the diet. We were 
also unable to directly assess the impact the dysregulated PUFA and oxylipin have on food 
aversion and anxiety in this cross-sectional study. We will address these limitations by a 
future longitudinal study and a blinded randomized placebo-controlled intervention trial in 
order to further identify the specific dietary or nutritional factors that may be targeted to 
reverse the metabolic dysregulation in AN.
Nutraceutical strategy implication
The primary treatment goal for AN covers three broad areas: restoration to a healthy weight, 
treatment of psychological issues related to the eating disorder, and reducing behaviors or 
thoughts that can lead to continued pathological eating and relapse. The current treatment 
strategies [79, 80] unfortunately have been proven to be ineffective and the death rate and 
relapse rate remain high.[2] Based on our finding, alternative or adjunct treatments may be 
developed through a rigorous randomized controlled trial targeting lipid metabolism and 
PUFA supplementation. If a specific formulation of n-6:n-3 ratio supplement can be shown 
to decrease anxiety and food aversion, improve eating behavior while restoring weight, such 
supplementation may lead to effective intervention for at risk individuals or adjunct 
treatment for patients. This study identified one of EPHX2’s biological mechanism in AN 
and revealed that in vivo sEH activity, dietary PUFAs, and cytochrome P450 metabolites all 
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contribute to risk. We identified unique lipidomic and metabolomic signatures that may 
serve as AN prognostic biomarkers to aid in the development of predictive diagnostics, 
preventative strategies and nutraceutical or pharmaceutical interventions and treatments.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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